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Accumulation of β-amyloid (Aβ) in the brain is an initiat-
ing factor in the pathological cascade leading to the devel-
opment and progression of Alzheimer’s disease (AD; Musiek 
and Holtzman, 2015). High concentrations of Aβ promote its 
aggregation into toxic species, such as oligomers and fibrils, 
within the brain extracellular space. The balance between Aβ 
generation and elimination determines the concentration 
of Aβ in the brain interstitial fluid (ISF). Four broad path-
ways have been identified that eliminate Aβ from the brain: 
transport across the blood–brain barrier (BBB), proteolytic 
degradation, cellular uptake, and bulk flow clearance. Sev-
eral of these pathways are impaired in individuals with AD 
(Preston et al., 2003; Nixon, 2007; van Assema et al., 2012). 
For instance, neprilysin and P-glycoprotein, an Aβ-degrading 
enzyme and an Aβ transporter at the BBB, respectively, are 
significantly reduced in human AD brain (Wang et al., 2005; 
Deo et al., 2014). In mouse models, deletion of either of these 
proteins increases brain Aβ levels, increases plaque load, and 
significantly prolongs the elimination rate of Aβ (or half-
life) from the brain (Cirrito et al., 2005; Farris et al., 2007). 
Clearance of Aβ from the CSF is impaired in individuals with 
AD (Mawuenyega et al., 2010), strongly suggesting that a key 
factor leading to Aβ accumulation is a defect in eliminating 
the peptide from the brain. Aβ is secreted into the extra-
cellular space, where it is soluble in the ISF under normal 
circumstances. The ISF pool of Aβ gives rise to pathological 
species, so mechanisms that regulate Aβ clearance from the 
ISF should impact AD pathogenesis. Aβ has a relatively short 
half-life compared with other proteins in the brain, indicat-
ing that some clearance mechanisms are fast-acting. Here, we 
use a novel microimmunoelectrode (MIE) to measure rapid 
changes in ISF Aβ metabolism in vivo.
Studying the temporal kinetics of Aβ within the brain 
ISF requires specialized techniques that specifically sample Aβ 
only from the ISF with the exclusion of peptide in other 
brain compartments (e.g., intracellular or membrane-bound) 
and can measure Aβ serially over time in a living mouse. In 
the past, we pioneered an in vivo microdialysis technique 
to measure ISF Aβ levels every 60 min over 3–5 d in mice 
(Cirrito et al., 2003, 2011). Although hourly sampling is still 
very useful, some studies require even faster temporal reso-
lution. We recently developed an electrochemical technique 
using MIEs to detect Aβ (Prabhulkar et al., 2012) and have 
adapted it to measure ISF Aβ every 60 s over several hours in 
the brains of living mice.
RES ULTS AND DIS CUS SION
In vitro characterization of the MIE
Amperometry is an electrochemical technique used to mea-
sure oxidation of a wide range of molecules, most notably 
small molecules such as serotonin and dopamine in the brain 
(Wightman, 1988). Several national security biohazard de-
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tectors, such as for anthrax, use amperometry in combina-
tion with antibodies to make the chip-based sensors specific 
for a protein (Sadik et al., 2003). We have developed a sim-
ilar amperometric, antibody-based approach to measure Aβ; 
however, these sensors can quantify a wide range of concen-
trations, take longitudinal measurements, and be implanted 
directly into the brain.
Aβ peptides in solution can be measured by exploiting 
the intrinsic electroactivity of Aβ (Vestergaard et al., 2005). 
The single tyrosine (Tyr) residue at position 10 of human Aβ 
bears a phenolic group that can be oxidized at an electrode 
surface. Oxidation releases electrons, which an electrode de-
tects as current; the amount of current is directly proportional 
to the number of Tyr residues present, or the concentration. 
Using square wave voltammetry (SWV), the voltage applied 
to a carbon fiber microelectrode is step-wise increased from 
0 to 1.0 V. When the electrode scans through ∼0.65 V, Tyr 
residues present in human Aβ oxidize, which is detected by 
the electrode as increased peak oxidation current. However, a 
0.65-V potential will oxidize a variety of molecules, includ-
ing all nearby Tyr within other proteins. We covalently at-
tached anti-Aβ40 or anti-Aβ42 antibodies, mHJ2 and mHJ7.4, 
respectively, to the MIE surface to provide specificity for each 
target (Fig. 1 A). Albumin is then absorbed to the electrode 
surface to limit nonspecific signal. Tyr oxidation is irreversible, 
therefore, Aβ peptides oxidized at the electrode surface can 
only be measured once. Additionally, once the tyrosine amino 
acids within albumin and antibody are initially oxidized, they 
will not contribute signal to the MIE over time.
The Aβ MIE is a 5-µm-diam, 30–60-µm-long cylinder- 
shape similar to the carbon fiber microelectrodes used in other 
in vivo studies (Roitman et al., 2008). Murine Aβ lacks a Tyr at 
position 10, so in theory, should not produce an oxidative signal 
using the MIE. As expected, robust oxidative signal is detected 
with the MIE in a solution of human Aβ, whereas only neg-
ligible signal is observed in a concentration-matched solution 
of murine Aβ (Fig. 1 B). Post-hoc ELI SAs were used to verify 
that the absolute concentration of murine and human Aβ were 
equal in these solutions. Importantly, the mHJ2 anti-Aβ40 anti-
body on the MIE binds to both mouse and human Aβ equally. 
Consequently, murine Aβ and wild-type mice serve as import-
ant negative controls to identify how specific the MIEs are at 
detecting only human Aβ as opposed to other electroactive 
molecules and proteins.
The antibody attached to the electrode is particularly 
important, as it provides specificity for the target and strongly 
influences MIE longevity. For the MIE to function, there 
must be excess antibody capable of binding fresh target; how-
ever, if all of the antibodies are bound to Aβ, the electrode 
becomes nonfunctional. MIEs are an application in which 
antibodies with a moderate affinity are ideal, so that the target 
has both an on-rate as well as a reasonable off-rate, allowing 
antibody binding capacity to remain open so new Aβ con-
tinues to bind. To prolong longevity of the MIE, we used 
an antibody specific for Aβ40 with moderate affinity (mHJ2 
KD = 14 nM determined by surface plasmon resonance) to 
allow for dissociation.
For our initial in vitro studies, we attached a mouse 
monoclonal antibody specific for Aβ40 (mHJ2) and evaluated 
the electrode response in solutions of Aβ40 and Aβ42 using SWV. 
Oxidation peak height increased as concentration of Aβ40 in-
creased (Fig. 2 A). At comparable concentrations in solution, 
the Aβ40 MIE is 52 times more selective for Aβ40 over Aβ42 
(Fig. 2 B). Similarly, attaching mHJ7.4, an anti-Aβ42–specific 
antibody, we also saw an increase in peak height correspond-
ing with increasing concentrations (Fig. 2 C). The Aβ42 MIE is 
15,000 times more selective for Aβ42 than for Aβ40 (Fig. 2 D). 
The higher selectivity of the Aβ42 MIE is likely caused by the 
higher affinity of the antibody. This difference in selectivity is 
particularly important in vivo, where there are very low con-
centrations of Aβ42 compared with Aβ40. We have intentionally 
designed the MIEs to have widely different selectivity for Aβ40 
and Aβ42 species to take into account practical considerations 
of electrode longevity and actual 40:42 ratios of the peptide in 
brain ISF. In the APP/PS1 mouse model used in these studies, 
the concentration of brain ISF Aβ42 is 10-fold lower than Aβ40. 
Consequently, the Aβ40 MIE actually has an effective 520-fold 
selectivity for Aβ40 versus Aβ42 in vivo.
Figure 1. Aβ-specific MIE. (A) Schematic 
of MIE. Anti-Aβ antibodies are covalently at-
tached to the electrode surface, and then un-
bound space is blocked with BSA. An electrode 
held at 0.65 V induces oxidation of Tyr amino 
acids. Oxidation releases an electron that the 
carbon fiber detects as current. The amount 
of current is proportional to the amount of 
Tyr present. Because many proteins in the ex-
tracellular space contain Tyr residues, the in-
clusion of an anti-Aβ antibody is a necessary 
factor that determines specificity of the elec-
trode. (B) Peak oxidation current of Aβ MIE in 
matched concentrations of human and mouse 
Aβ (n = 3; mean ± SEM).
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In vivo MIEs to measure brain ISF Aβ
To measure rapid changes in brain ISF Aβ in the mouse hip-
pocampus, we stereotaxically implanted Aβ40 MIEs into the 
hippocampus of anesthetized APP/PS1 and wild-type mice 
(Fig. 3 A). A large oxidation peak is observed at ∼0.65 V in 
APP/PS1 mice, whereas only a negligible oxidative signal 
is seen in scans of wild-type mice (Fig. 3 B). Variability in 
individual MIE length and sensitivity leads to variable oxi-
dation peak heights for each electrode; therefore, each MIE 
must be calibrated against known concentrations of Aβ. The 
mean concentration of human Aβ40 in the ISF, as measured 
by the MIE, is 128.16 ng/ml. Within a single animal, the 
minute-to-minute variability of Aβ is 9.89 ± 1.88 ng/ml 
(mean ± SEM). These fluctuations appear to be biologically 
driven by rapid changes in Aβ production and clearance. In 
contrast, levels of murine Aβ in wild-type mice are essentially 
undetectable (Fig. 3 C). From these data, we infer that the 
MIE is at least 8,000-fold more selective in vivo for human 
Aβ as opposed to any other Tyr present in the brain ISF.
To evaluate stability of the MIE in vivo over time, we 
normalized the concentration of ISF Aβ at each time point 
to the mean baseline concentration from minute 10 to 25 for 
each mouse (Fig. 3 D). Concentrations are stable until minute 
118, after which measurements have a small but significant 
decrease from baseline levels (P = 0.02). These results indicate 
that the MIE loses sensitivity after ∼2 h in vivo; therefore, 
measurements beyond 120 min need to be corrected for this 
decease. The decrease in ISF Aβ after 2 h appears to be pri-
marily a result of electrode sensitivity and possibly a small re-
duction in ISF Aβ levels caused by anesthesia. To verify using 
a complementary technique, we used in vivo microdialysis 
to measure ISF Aβ every hour before and during isoflurane 
anesthesia. ISF Aβ levels decrease by 14% during the first 3 h 
of isoflurane anesthesia; however, this was not a significant 
change in Aβ (n = 4, P = 0.135). For the following MIE 
studies, we only sampled Aβ for 100 min after implantation 
to avoid this confounding factor.
MIE technology
MIEs provide a powerful technology to assess the rapid dy-
namics of protein changes in brain within short periods. This 
provides a temporal resolution to measure proteins in vivo 
every 60 s, which was previously not feasible. One of the ad-
vantages, and disadvantages, of the Aβ MIE technique is that 
it only detects human Aβ species. Although wild-type mice 
serve as a negative control, this technique limits studies to 
those involving transgenic/knock-in mouse models that pro-
duce the human form of Aβ. The 5-µm-diam of the MIEs is 
smaller than most neuron cell bodies, so the electrodes create 
very little damage during insertion. Implantation of micro-
electrodes has been shown to activate microglia within 6 h, 
but not within the short timeframe of our study (Kozai et al., 
2012). We examined tissue sections for evidence of lesions or 
microbleeds resulting from acute MIE implantation; in many 
cases tissue disruption caused by surgery was evident on the 
brain surface; however, the exact site of the MIE tip was very 
Figure 2. In vitro characterization of MIEs for Aβ40 and Aβ42. Oxidation peak height of MIEs coated with either (A) an Aβ40 specific antibody (mHJ2; 
n = 6) or (C) Aβ42-specific antibody (mHJ7.4; n = 7). (B) Representative concentration of Aβ measured using Aβ40 MIE in matched concentrations of Aβ40 and 
Aβ42 (n = 3; mean ± SEM). Representative concentration of Aβ measured using Aβ42 MIE in matched concentrations of Aβ40 and Aβ42 (n = 3; mean ± SEM; D).
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small and normally undetectable by histology. Consequently, 
tissue damage is only a small concern using this technique.
MIEs only function for 2 h before starting to lose sensi-
tivity. In contrast, our in vivo microdialysis technique samples 
Aβ every hour, but lasts for 3–5 d (Cirrito et al., 2003). The 
MIE and microdialysis approaches complement each other 
by enabling the study of both brief and prolonged events that 
regulate ISF Aβ metabolism. Measuring protein concentra-
tions every 60 s enables us to study fast-acting mechanisms for 
Aβ production and clearance, which could not previously be 
studied. Specificity of the electrode depends on the antibody 
attached and the presence of an electroactive amino acid (such 
as tyrosine, tryptophan, or cysteine); therefore, it is possible 
that MIEs can be developed to detect other proteins as well.
Rapid measurement of Aβ half-life in vivo
P-glycoprotein (Pgp) removes brain ISF Aβ by transporting 
it across the BBB (Cirrito et al., 2005; Hartz et al., 2010). 
Pgp is expressed on the luminal surface of brain endothelial 
cells and transports the peptide out of those cells and into 
blood. Pgp-null mice (mdr1a/1b double knockout mice) 
have significantly impaired BBB transport of Aβ40; however, 
Aβ42 transport is minimally affected. Pgp-null mice crossed to 
Tg2576 APP transgenic mice also have significantly greater 
plaque load, and similarly, individuals with low Pgp expression 
have higher Aβ deposits in brain (Vogelgesang et al., 2002).
Using MIEs to measure real-time and rapid changes in 
ISF Aβ40, we evaluated clearance under normal conditions 
and after Pgp inhibition. Previous studies in rodents have 
shown XR9576 effectively blocks Pgp-mediated transport 
quickly, with maximum activity inhibited 30 min after in-
jection, which then declines slowly due to low compound 
elimination (Bankstahl et al., 2008). We measured levels of 
XR9576 in brain tissue at 1 h after injection and found mean 
levels to be 533.0 ± 68.11 µM, where the IC50 for inhibition 
in vivo is 1.05 µM (Wanek et al., 2015). Therefore, we pre-
treated one group of APP/PS1 mice with XR9576 for 1 h 
before measuring Aβ40 clearance. Under anesthesia, we in-
serted an Aβ40 MIE into the hippocampus to measure baseline 
ISF Aβ levels for 15 min before administering Compound E, 
a γ-secretase inhibitor (GSI), to block Aβ generation. Inhib-
iting Pgp alone resulted in a 305% increase in baseline levels 
of Aβ40 compared with controls (Fig. 4 A). The increase in 
ISF Aβ detected with the MIE is much greater than previous 
studies using microdialysis (Cirrito et al., 2005). This is likely 
because of the difference of awake versus anesthetized mice 
and because the two techniques detect slightly different pop-
ulations of ISF Aβ in vivo.
Treating mice with a GSI rapidly blocks Aβ genera-
tion, enabling us to assess the elimination of existing peptide 
present within the ISF. From these data, we can calculate an 
in vivo elimination half-life of endogenous Aβ. Although 
the absolute levels of Aβ40 were significantly higher in the 
XR9576-treated mice, ISF Aβ40 concentration still declined 
quickly after GSI treatment in both groups (Fig. 4 B). Com-
pound E drug levels reach 395 nM brain tissue within 5 min 
after intraperitoneal injection (Fig.  4  C). This concentra-
tion is ∼1,200-fold higher than the IC50 of Compound E to 
block APP cleavage into Aβ (IC50 in CHO cells is 300 pM; 
Seiffert et al., 2000). Compound E levels in the brain de-
crease substantially by 60 min after injection; however, they 
still remain 30-fold higher than the IC50 (Fig. 4 C). Percent 
changes in ISF Aβ40 after GSI administration were trans-
formed into log values to calculate rate of clearance over 
time (Fig.  4 D). We analyzed the overall rate of clearance 
in both groups from minutes 5–60, which was significantly 
Figure 3. In vivo MIE measures ISF Aβ in 
APP/PS1 mouse model. (A) Stereotaxic place-
ment of MIE, reference and counter electrodes 
on mouse skull, with representative SWV peaks 
from the hippocampus of an APP/PS1 mouse 
and WT littermate. (B) Traces measuring 
human and murine Aβ with baseline subtrac-
tion are shown on the same scale to highlight 
the differences in peak height observed, while 
inset shows background level detected in the 
WT mouse. (C) ISF Aβ40 concentrations over 
180 min in APP/PS (n = 6) and WT (n = 3) mice. 
(D) Data in Panel C normalized to percent of 
baseline ISF Aβ40 levels of each APP/PS1 mouse 
show stable levels until 118 min after MIE in-
sertion (ANO VA post hoc analysis, P = 0.02).
681JEM Vol. 213, No. 5
prolonged by 275% in the XR9576-treated mice compared 
with control mice (P = 0.012; Fig. 4 E). The overall pattern 
of changes observed in ISF Aβ after GSI administration and 
Pgp inhibition using the MIE are comparable to what we 
have previously reported (Cirrito et al., 2005).
Interestingly, however, the rates of clearance were not 
uniformly different throughout the entire course of the study; 
the semi-log plots of both groups actually show similar clear-
ance rates up until 15 min, where they then begin to diverge 
(Fig. 4 D). Using a modified curve stripping analysis, we iso-
lated two different slopes in the clearance profile. We found 
no significant differences in the clearance rate during the ini-
tial 15 min after GSI treatment (Fig. 4 F); however, the second 
phase in the clearance rate (minutes 16–60) was significantly 
slower in XR9576-treated mice (P = 0.001; Fig.  4  G). To 
determine if acute inhibition of Pgp influenced expression of 
low-density lipoprotein-1 (LRP1), or other genes related to 
APP processing or Aβ clearance, we examined mRNA levels 
in brain tissue 2 h after XR9756 treatment (see Materials and 
methods for specific genes). We did not find significant dif-
ferences in mRNA expression levels in the brain, indicating 
the drug treatment is not affecting global expression of genes 
related to APP processing or Aβ elimination (n = 6/group; 
P = 0.08–0.94; cut off for multiple comparisons, P = 0.004). 
Similarly, LRP1 protein levels did not change in hippocam-
pus after XR9576 administration (n = 9/group, P = 0.35). 
However, we did not assess expression in blood vessels specifi-
cally. Pgp does not appear to play a substantial role in brain Aβ 
clearance at high concentrations, but is a critical mechanism 
when Aβ levels decrease below a certain threshold.
Kinetics of Aβ clearance in vivo
Clearance of Aβ falls into four main categories: active BBB 
transport into the periphery, cellular uptake, proteolytic deg-
radation, and passive bulk flow elimination. Both LRP1 and 
Pgp are expressed by endothelial cells (abluminally and lu-
minally, respectively) and act cooperatively to transport Aβ 
from the perivascular space out of the brain into blood (Shi-
Figure 4. Rapid measurement of ISF Aβ40 clearance after Pgp inhibition. (A) Absolute baseline concentrations of ISF Aβ40 calculated using calibrated 
MIEs in the hippocampus of APP/PS1 mice are significantly increased (Student’s t test; *, P = 0.008) 60 min after XR9576 treatment (n = 8; mean = 283.9 
± 80.38; 80 mg/kg) compared with control mice (n = 15; mean = 99.12 ± 19.28). (B) ISF Aβ40 concentrations decrease in both groups after Compound E 
administration to block Aβ production. (C) Compound E levels in the brain reach ∼1,200-fold IC50 within 5 min of injection and remain ∼30-fold higher 
than IC50 at 60 min. (D) Log plot of percent Aβ change from baseline versus time for both XR9576-treated mice (n = 5) and control (n = 6) shows initial rates 
of clearance are very similar then begin to diverge 16 min after γ-secretase inhibition. (E) Overall half-life of Aβ40 is significantly slowed (Student’s t test; 
*, P = 0.016) after XR9576 treatment (control mean = 23.30 ± 4.55 min; XR9576 mean, 71.05 ± 16.01 min). Further analysis of the slopes between groups 
suggests two phases in Aβ40 clearance over time. Statistical analysis reveals no difference in rates over the first 15 min (F; Student’s t test, P = 0.698; control 
mean = 22.26 ± 4.09 min; XR9576 mean, 27.1 ± 12.41 min); however, rates from 16–60 min are significantly slowed in XR9576-treated mice (G; Student’s 
t test; *, P = 0.001; control mean, 30.44 ± 7.71 min; XR9576 mean, 84.08 ± 10.85 min). Error bars represent ± SEM.
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bata et al., 2000; Deane et al., 2004; Zlokovic et al., 2010). 
LRP1 and several family members have an additional role 
of cellular uptake of Aβ within the brain (Castellano et al., 
2012; Kanekiyo et al., 2013). Proteases such as neprilysin and 
matrix metalloproteinases (MMPs) degrade extracellular Aβ 
(Farris et al., 2007). Lastly, bulk flow mechanisms, including 
the glymphatic system, clear Aβ out of the ISF as part of the 
normal, passive fluid turnover (Xie et al., 2013).
By measuring ISF Aβ very rapidly, we were able to de-
tect multiple rates of Aβ elimination from the brain. Our data 
using MIEs for rapid sampling determined that Aβ clearance 
does not follow first-order kinetics, as previously reported by 
our group using microdialysis (Cirrito et al., 2003). Instead, 
the rate of elimination varies with concentration. The initial 
rate of clearance, when ISF Aβ concentrations are high, has 
a very short half-life. However, as Aβ concentrations decline, 
the half-life is significantly longer. It is possible that the var-
ious Aβ clearance mechanisms contribute to different clear-
ance rates. It will be necessary to explore these effects by 
blocking individual pathways and measuring rapid clearance 
to determine the role each mechanism plays in the immediate 
removal of Aβ from the ISF. Our data demonstrate that Pgp 
is critical for the slower elimination rate of Aβ at the BBB, 
which appears to account for an overall greater percentage 
of ISF Aβ clearance than the faster pathway. These results are 
similar to those reported by (Qosa et al., 2014) in that BBB 
clearance accounts for a greater percentage of Aβ40 clearance 
than proteolytic degradation, and Pgp inhibition slows this 
clearance pathway specifically.
Our data suggest that the speed and efficiency of Aβ 
clearance pathways may be different. A therapeutic strategy 
aimed at rapid clearance at only high concentrations may be 
different than a strategy that is designed for a sustained, pos-
sibly larger, suppression of Aβ. And if multiple pathways are 
targeted, then enhancing clearance mechanisms with different 
properties and rates could be beneficial.
MAT ERI ALS AND MET HODS
Animals. All experimental procedures involving animals 
were approved by the Animal Studies Committee at Wash-
ington University. We bred APP/PS1+/− hemizygous mice 
(Jankowsky et al., 2004) to wild-type C3H/B6 mice (The 
Jackson Laboratory), and then used the APP/PS1+/− off-
spring, or wild-type littermates, for experiments at 3 mo 
of age, before Aβ deposits are observed in this model. These 
mice contain a PS1ΔE9 mutation and human APP Swedish 
mutation that were inserted into a single locus. Animals were 
screened for the PS1 and APP transgenes by polymerase 
chain reaction from tail DNA. Male and female littermate 
mice were distributed between experimental groups.
MIE preparation. MIEs were prepared following our previ-
ously described methods (Prabhulkar et al., 2012). Carbon 
fiber microelectrodes were used as the platform sensor be-
cause of their high signal-to-noise ratio, biological compati-
bility, and small size. Carbon-based electrodes have also been 
proven to sensitively detect Tyr oxidation (Vestergaard et al., 
2005). In brief, a single length of carbon fiber (5-µm-diam; 
GoodFellow Corp.) was aspirated into a glass capillary tube 
(0.4-mm inner diameter, 4 inch length; A-M Systems), shaped 
using a pipette puller (Narishige PE-22), and attached to an 
insulated silver wire using conductive silver adhesive paste 
(Ted Pella, Inc.). The junction between the wire and the glass 
capillary tube was sealed using heat shrink tubing (NTE 
Electronics). The carbon fiber was cut using microsurgical 
scissors (World Precision Instruments, Inc.) to a length of 
30–60 µm. To enhance binding of the capture antibody, the 
microelectrodes were pretreated using a triangular waveform 
from 0 to 3 V for 70 s in PBS, or in 150 mM NaCl solution 
(pH, 10) at 1.2 V for 4 min. The carboxylic groups on the 
carbon fiber surface were activated by application of 0.4 M of 
EDC and 0.1 M of NHSS solutions (Thermo Fisher Scien-
tific) to form a semistable reactive amine NHS ester. The ac-
tivated microelectrodes are placed in a solution of antibody 
(e.g., mHJ2 for Aβ40 or mHJ7.4 for Aβ42) and incubated at 
room temp for 10 min, and then 4°C overnight. After anti-
body attachment, MIEs were incubated with 0.05% ethanol-
amine to deactivate reactive amine sites and then 0.1% BSA 
to block nonspecific protein-binding sites.
In vitro MIE studies. In vitro calibration of the MIEs before 
experiments were conducted using a CH Instruments 660D 
Electrochemical Workstation with PicoAmp booster (CH In-
struments Inc.). A conventional three-electrode cell consisting 
of an Ag/AgCl reference electrode (1 M KCl), and a platinum 
wire as a counter electrode was used in all experimental pro-
cedures. Synthetic human Aβ40, Aβ42, and mouse Aβ40 (Amer-
ican Peptide Co.) were prepared in fivefold serial dilutions 
ranging from 1 µg to 64 pg in 0.1% BSA in PBS. SWV was 
used to monitor the response of the electrode in different 
concentrations of Aβ. Actual concentration in each Aβ sample 
was determined by sandwich ELI SA after each experiment. 
Aβ concentrations using the MIE were calculated based on 
standard curve values from the calibration ELI SA. SWV pa-
rameters used were: Init E (V) = 0; Final E (V) = 1; Inc.r E 
(V) = 0.004; Amplitude (V) = 0.04; and Frequency (Hz) = 15.
In vivo MIE studies. To maintain consistency with our in vitro 
characterization of the Aβ40 MIE, we used a three electrode 
design in vivo as well. In addition to the MIE, a stainless steel 
bone screw used as a counter electrode, and an Ag/AgCl ref-
erence electrode (InVivo Metrics) were implanted into the 
brain of preplaque (3–4 mo old) APP/PS1+/− transgenic mice 
and wild-type littermates. All electrodes were stereotaxically 
implanted in to the brains of APP/PS1+/− mice under isoflu-
rane anesthesia. Mice were placed on a heating pad to main-
tain body temperature. For these experiments, Aβ40 MIEs 
were inserted into the hippocampus at coordinates: bregma 
–3.1 mm, 2.6 mm lateral to midline, and 1.7 mm below 
dura mater. Repetitive SWV scans were run every 60  s for 
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up to 180 min. The stereotax was enclosed in a faraday cage 
to reduce electrical noise. Electrodes were attached to a CH 
Instruments 830D Electrochemical Analyzer with PicoAmp 
booster. All electrodes were calibrated against known con-
centrations of Aβ40 before the experiment, and only MIEs 
showing increasing response to increasing concentrations of 
Aβ40 in vitro were used for in vivo experiments.
Aβ ELI SA. ISF Aβ levels were assessed using sandwich ELI 
SAs as previously described (Cirrito et al., 2011). In brief, to 
assess Aβ40 and Aβ42 in MIE calibration solutions, mouse 
monoclonal antibodies (HJ2 or HJ7.4, respectively) were 
used to capture and a biotinylated central domain Aβ- 
specific antibody (HJ5.1) was used to detect, followed by 
streptavidin-poly-HRP-20 (Fitzgerald Industries). All ELI 
SA assays were developed using Super Slow ELI SA TMB 
(Sigma-Aldrich) and absorbance read on an Epoch plate 
reader (Bio-Tek) at 650 nm.
Aβ elimination half-life. ISF Aβ half-life was determined sim-
ilar to our previously described method using microdialysis 
(Cirrito et al., 2003). MIEs were inserted into the hippocam-
pus and SWV scans were run until the baseline became stable 
(10–20 min). After baseline stabilization, mice were adminis-
tered a potent, blood–brain permeable γ-secretase inhibitor, 
Compound E (synthesized by AsisChem; 30 mg/kg) intraper-
itoneally to rapidly block Aβ production. ISF Aβ levels were 
measured by SWV scans every 60 s for 60–90 min. The half-life 
of ISF Aβ was calculated on the basis of the slope of the semilog 
plot of percent change in Aβ versus time. Only Aβ values that 
were continually decreasing were included in half-life analysis 
(within the 60 min after Compound E administration).
Quantitative real-time PCR (qRT-PCR). 3-mo-old mice were 
treated with XR9576 (80 mg/kg i.v.) or vehicle (equal volume 
5% dextrose). Mice were sacrificed 2 h later, and their brains 
were microdissected and frozen on dry ice. Total RNA were 
extracted from cortex using the RNeasy Mini kit (QIA GEN) 
and reverse transcribed using the High Capacity cDNA Re-
verse Transcription kit (Invitrogen). The APP processing- 
related genes evaluated were as follows: Amyloid precur-
sor protein (APP), Presenilin 1 and 2 (PSEN1 and PSEN2) 
Nicastrin, Anterior pharynx-defective 1 (APH-1), β-secretase 
1 (BACE1), A Disintegrin and metalloproteinase domain- 
containing protein 10 and 17 (ADAM10 and ADAM17). 
The Aβ clearance-related genes evaluated were as follows: 
P-glycoprotein (Pgp), low density lipoprotein 1 (LRP1), in-
sulin degrading enzyme (IDE), Neprilysin (NEP), and matrix 
metalloproteinase 2 and 9 (MMP2 and MMP9). Individual 
primers were designed using Harvard Medical School Primer 
Bank. qRT-PCR was performed using the Fast SYBR Green 
Master Mix (Applied Biosystems) in ABI 7900HT (Applied 
Biosystems) with the default thermal cycling program. Dis-
sociation curves were analyzed after qPCR assay to confirm 
primer efficacy. Relative mRNA levels were calculated using 
the ΔΔCt method, normalizing cDNA levels to endogenous 
mouse GAP DH. Student’s t tests with p-value correction for 
multiple comparisons were used to analyze changes in gene 
expression using the GraphPad Prism 6 software.
LRP1 protein levels in brain tissue. Hippocampi from control 
and XR9576-treated mice were lysed in buffer containing 
150 mM NaCl, 50 mM Tris, 0.5% deoxycholic acid, 1% Tri-
ton X-100, 0.1% SDS, 2.5 mM EDTA, and broad spectrum 
protease inhibitors. Protein concentration was determined in 
each sample using a Micro BCA Protein Assay kit (Thermo 
Fisher Scientific). 15 µg of protein for each sample was used 
for SDS-PAGE using 4–12% Bis-Tris gels with MES running 
buffer (Life Technologies). Rabbit polyclonal anti-LRP1 an-
tibody was produced in G. Bu’s laboratory (Mayo Clinic, 
Jacksonville, FL), followed by goat anti–rabbit HRP (Santa 
Cruz Biotechnology). As a loading control, blots were stripped 
and reprobed with mouse anti-GAP DH (Sigma-Aldrich) and 
sheep anti–mouse peroxidase (GE Life Sciences). Blots were 
imaged on a ImageStation 440CF (Kodak) and bands quanti-
fied using 1D image analysis software (Kodak). LRP1 bands 
were normalized to GAP DH bands, and then for each gel the 
control-treated and XR9576-treated tissues were normalized 
to the mean of control bands intensity. LRP1 protein levels 
were compared between groups by unpaired Student’s t test.
Compound E and XR9576 levels in brain tissue. Samples 
were extracted with indicated volume of 45% methanol/45% 
acetonitrile/8% water/2% formic acid containing 1  µM 
LY411575 as internal standard so that each hemisphere was 
extracted at a concentration of 200 mg/ml. After lysis by 
shaking for 5 min at 20 Hz in the TissueLyserII (QIA GEN) 
with a 4-mm stainless steel ball, samples were centrifuged and 
then filtered through a 0.8-µm PES spin filter (Sartorius). Fil-
tered samples were diluted 1:20 with LC-MS grade water 
and centrifuged to remove any particulates. Samples were an-
alyzed on a Q-Exactive Mass Spectrometer (Thermo Fisher 
Scientific) operated in positive profile mode at a resolution 
setting of 70,000 with a scan range of m/z 100–500. Spectra 
were internally calibrated using the lock mass feature against 
ever present airborne contaminants. The system was equipped 
with a 1200 Capillary LC (Agilent) and a 0.5 × 100 mm 3 µm 
PLR PS column (Higgins Analytical). Solvents were 100% 
water (A) and acetonitrile (B) with 0.1% formic acid. The 
chromatographic gradient was as follows: 0% B from 0–4 min 
followed by a linear ramp up to 100% B over 6 min, a hold 
at 100% B for 3 min, a 2-min ramp back down to 0% B, and, 
finally, a reequilibration time of 15 min. 1 µl of sample was 
injected such that 50 fmol of internal standard was loaded on 
column each time for data normalization. Data were analyzed 
using the QuanBrowser application of Xcalibur (Thermo 
Fisher Scientific). Compound E and XR9576 concentrations 
in mouse brain were calculated based on comparing normal-
ized area counts with an external calibration curve prepared 
in control mouse brain extract.
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Statistical analysis. All in vitro measurements were per-
formed in triplicate and the mean of the three SWV scans 
was used for analysis. All current responses recorded were 
subtracted from background and fit to baseline for peak anal-
ysis using CH Instruments software. Results are expressed as 
mean ± SE. Differences in clearance rates between groups 
were analyzed in GraphPad Prism software using T-tests; re-
peated measures ANO VA with Bonferroni post-hoc tests was 
used to analyze percent changes in baseline levels over time. 
Statistical significance in all analyses was set at P < 0.05.
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